March 1st 2023
Sarilumab is a fully human monoclonal antibody indicated for patients with polymyalgia rheumatica who had an inadequate response to corticosteroids or are unable to tolerate corticosteroid taper.
January 18th 2023
Tofacitinib, Biologic DMARDs Associated with Higher Risk of Herpes Zoster in Patients with Rheumatoid ArthritisAugust 15th 2022
Treatment with biologic disease-modifying antirheumatic drugs associated with a higher overall risk, incidence, and recurrence of herpes zoster for patients with rheumatoid arthritis.
Clinical Overview: Cyletzo, a Biosimilar Version of AdalimumabJuly 19th 2022
Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
Following Supreme Court Reversal of Roe v. Wade, Some Patients Fear Limited Access to MethotrexateJuly 13th 2022
Some anti-abortion laws may lead to legal action against health care providers who prescribe or provide medications that can be used to induce abortions.
Daily Medication Pearl: Tocilizumab (Actemra)June 22nd 2022
Tocilizumab (Actemra) is indicated for treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
Evaluation of Factors Driving Rheumatoid Arthritis Moderate to High Disease Activity on Routine Assessment of Patient Index Data 3 Score
Utilization of the RAPID3 tool can be a beneficial way for pharmacists to complete disease activity assessments without physically seeing the patient in a clinic setting.
FDA Approves New Indication for Rituximab Biosimilar for Rheumatoid ArthritisJune 7th 2022
In addition to the new approval for rheumatoid arthritis, Riabni has already been approved for the treatment of adult patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
Multisite Health-Systems Specialty Pharmacy Study Evaluates Adherence to Self-Administered Biologic Disease-Modifying Antirheumatic Drugs
High adherence to treatment is a key first step toward better patient outcomes, including sustained disease control or remission.
How Data Can Help Demonstrate the Value of the Health-System Specialty PharmacyMarch 10th 2022
Insurers, accountable care organizations, and manufacturers increasingly look for demonstrable clinical outcomes as proof for reimbursement or access to limited distribution networks.
Daily Medication Pearl: Upadacitinib (Rinvoq)March 4th 2022
Upadacitinib (Rinvoq) is a Janus kinase (JAK) inhibitor being investigated to treat rheumatoid arthritis, Crohn disease, ulcerative colitis, atopic dermatitis, psoriatic arthritis, axial SpA giant cell arteritis, and Takayasu arteritis
FDA Approves Abatacept With Calcineurin Inhibitor for Prophylaxis of Acute Graft Versus Host DiseaseDecember 17th 2021
Abatacept is also approved for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe polyarticular juvenile idiopathic arthritis for children 2 years of age and older.
Study Suggests Some Patients Taking Anti-Inflammatory Drugs May Have Weaker Immune Response to COVID-19 VaccinesJune 16th 2021
A lower antibody response found in one-fourth of patients taking methotrexate does not necessarily mean that these patients are not protected against COVID-19.
Novel Immune Checkpoints Could Combat Cancer-Related Immunosuppression, Autoimmune DiseasesJune 11th 2021
After identifying 3 novel checkpoints involved in immunosuppression and autoimmune diseases, investigators developed recombinant proteins that could be used in this patient population.
Study: Certain Immunosuppressing Drugs Do Not Increase Risk for Contracting COVID-19September 23rd 2020
A recent study found that patients on immunosuppressive therapy for common skin and rheumatic diseases, such as psoriasis and rheumatoid arthritis, are not at an increased risk for contracting COVID-19.